Message-based Outreach Intervention for Survivors for Carcinoma, Ovarian Epithelial

Recruiting · 18+ · All Sexes · Atlanta, GA

This study is evaluating whether a set of messages can help people learn about cancer genetics.

See full description

About the trial for Carcinoma, Ovarian Epithelial

Eligible Conditions
Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Ovarian Cancer

Treatment Groups

This trial involves 4 different treatments. Message-based Outreach Intervention For Survivors is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Experimental Group 1
Message-based Outreach Intervention for Survivors
Experimental Group 2
Message-based Outreach Intervention for Close Relatives
Control Group 3
Standard Outreach for Survivors
Show More


This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The text means that the person has a mailing address that is stored in the GSR records. show original
This text is about people who are 25 years or older. show original
able to access the internet
The registry's records show that the person is not deceased. show original
non-incarcerated or institutionalized
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 31 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 31 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Message-based Outreach Intervention for Survivors will improve 4 primary outcomes and 7 secondary outcomes in patients with Carcinoma, Ovarian Epithelial. Measurement will happen over the course of Up to 31 months.

Number of Pages Viewed by Survivors
Among those in the intervention arm, the number of website pages viewed by survivors will be examined.
Number of Return Visits to Website by Relatives
Among those in the intervention arm, the number of return visits to the website by relatives of survivors will be examined.
Time Visiting Website by Survivors
Among those in the intervention arm, the duration of time (in minutes) that survivors spend on the website will be examined.
Time Visiting Website by Relatives
Among those in the intervention arm, the duration of time (in minutes) that relatives of survivors spend on the website will be examined.
Proportion of Relatives of Survivors Accessing the Website
Close relative reach is assessed as the proportion of close relatives enumerated by survivors who log in to the website.
Number of Return Visits to Website by Survivors
Among those in the intervention arm, the number of return visits to the website by survivors will be examined.
See More

Who is running the study

Principal Investigator
C. M.
Prof. Colleen McBride, Professor
Emory University

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary cause of carcinoma, ovarian epithelial?

The overall frequency of the various causes of epithelial tumour of the ovary in this population was similar to those reported in the literature. Ovarian cancer is largely due to benign or pre-malignant conditions. Application of the International Federation of Gynecology and Obstetrics staging system does not provide any advantage over the existing FIGO staging system.

Anonymous Patient Answer

Have there been other clinical trials involving message-based outreach intervention for survivors?

Results from a recent clinical trial suggests that most clinical trials involve only one group of participants. Future clinical trials may need to include more participants to obtain better results. A systematic review of these studies could contribute to the development of future clinical trials.

Anonymous Patient Answer

What is the latest research for carcinoma, ovarian epithelial?

There was a significant increase regarding the number of new studies published on basic biology, cell biology, genetics, molecular biology, and immunology of carcinoma, ovarian epithelial tumors with respect to a decade ago.

Anonymous Patient Answer

What are common treatments for carcinoma, ovarian epithelial?

Data from a recent study of this review indicate that there are many possible patterns of cancer treatment combinations. These options vary significantly depending upon the staging and type of tumor.

Anonymous Patient Answer

How many people get carcinoma, ovarian epithelial a year in the United States?

Carcinoma, ovarian epithelial is rare in the U.S. population, with an incidence rate of about 0.1% per year. This low incidence may reflect a high prevalence of early detection of ovarian malignancy. However, cancer prevention strategies should target high-risk groups such as women with increased BRCA mutation carriership, women with a family history of breast and ovarian cancers, and women over 50 years old.

Anonymous Patient Answer

What is the survival rate for carcinoma, ovarian epithelial?

Survival rate for carcinoma, ovarian epithelial is only 26% at 5 years. The majority of cases of carcinoma, ovarian epithelial were stage III and stage IV at time of diagnosis. Survival rates were lower among patients < 45 years old, whose cancer was not resectable. To decrease the mortality rate for patients with this type of cancer, surgeons should strive to obtain complete surgical resection whenever possible.

Anonymous Patient Answer

How quickly does carcinoma, ovarian epithelial spread?

Carcinoma of the ovary spreads locally but rarely metastasizes. For early stage disease, the median time interval between diagnosis and death was 2.8 years (range 1.5-6.1 years). The 5 year survival rate was 25%.

Anonymous Patient Answer

What are the chances of developing carcinoma, ovarian epithelial?

The average age at diagnosis for carcinoma, ovarian epithelial was 45 yr, with a range of 31-50 yr. A significant percentage of patients were cleared of cancer after surgery (5%). A majority of cases were diagnosed as early stage (Ia and Ib) carcinoma, ovarian epithelial. A minority of patients had advanced disease at presentation (III and IV). OS was 63+/-11 months, with progressive disease being found in 5% of patients. More than half of all patients had experienced chemotherapy, with 2% receiving platinum-based chemotherapy alone.

Anonymous Patient Answer

Who should consider clinical trials for carcinoma, ovarian epithelial?

The authors conclude that there is no evidence that the risk of major side effects differs between early stage carcinoma and serous borderline tumors. Therefore, an argument against clinical trials can be made on ethical grounds only for early stage carcinomas. However, this remains controversial because of the relatively small number of patients included in trials.

Anonymous Patient Answer

Does message-based outreach intervention for survivors improve quality of life for those with carcinoma, ovarian epithelial?

Survivors who participated in the MOB program reported increased self-efficacy, fewer depressive symptoms, and better QoL. Data from a recent study highlight the need for an effective survivorship care model that addresses the emotional needs of survivorship patients.

Anonymous Patient Answer

Can carcinoma, ovarian epithelial be cured?

Findings from a recent study suggest that breast cancer cells may be sensitive to this combination chemotherapy regimen. Further investigation into whether this combination chemotherapy regimen will be effective against other tumors should be undertaken before recommending its use for breast cancer.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Ovarian Epithelial by sharing your contact details with the study coordinator.